Clinical Trial Update: Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study of LBH589 (panobinostat) in patients with recurrent or refractory Hodgkin lymphoma or non-Hodgkin lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• LBH589 (panobinostat)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma | Phase 1 | Status: TERMINATED